Back to top

LACOG 0821 – AMIGO-1

  /    /  LACOG 0821 – AMIGO-1

A single arm, phase 2 study of amivantamab, lazertinib and pemetrexed for first-line treatment of recurrent / metastatic non-small cell lung cancers (NSCLCs) with EGFR mutations

Type of Study: Clinical Trial

Sponsor / Support: LACOG, Janssen

Primary Objectives: To evaluate the 18-month progression-free survival (PFS) rate of amivantamab, lazertinib and pemetrexed for first-line treatment of recurrent / metastatic non-small cell lung cancers (NSCLCs) with EGFR mutations.

Design: Interventional, single-arm, phase II trial  

Sample Size: 49 patients.

Principal Investigator: William Nassib William Junior

Countries LATAM: Brazil

Clinicaltrials.gov Identifier: NCT05299125

Download the study poster presented at the 2023 ESMO Congress here:

The study is open to patients participation in the following research sites:

Hospital de Amor / Barretos / SP / Brazil

Irmandade da Santa Casa de Misericórdia de Porto Alegre / Porto Alegre / RS / Brazil

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto USP / Ribeirão Preto / SP / Brazil

Hospital Evangélico de Cachoeiro do Itapemirim / Cachoeiro de Itapemirim / ES / Brazil

Pronutrir / Fortaleza / CE / Brazil

ICESP - Instituto de Câncer do Estado de São Paulo / São Paulo / SP / Brazil

Hospital Erasto Gaertner / Curitiba / PR / Brazil

CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS / Porto Alegre / RS / Brazil

Hospital de Base de São José do Rio Preto / São José do Rio Preto / SP / Brazil

Liga Norte Riograndense / Natal / RN / Brazil

A Beneficência Portuguesa / São Paulo / SP / Brazil

Centro de Tratamento de Tumores Botafogo (Oncoclínicas) / Rio de Janeiro / RJ / Brazil

Núcleo de Pesquisa São Camilo - IBCC Oncologia / São Paulo / SP / Brazil

INCA - Instituto Nacional de Câncer / Rio de Janeiro / RJ / Brazil

Ongoing studies

Breast
GBECAM 0115 – AMAZONA III
LACOG 0115 – LORELEI
LACOG 0221 – BRAVE
LACOG 0413 – Male Breast Cancer
LACOG 0419 – NEOSAMBA
LACOG 0615 – LATINABreast
LACOG 0715 – PALLAS
LACOG 2118 – ALEXANDRA/IMpassion 030

Gastrointestinal
LACOG 0119
LACOG 0222 – GASPAR
LACOG 0421 – ACTION HIV
LACOG/GTG 1318 – Anal Registry

Genitourinary
LACOG 0121 – PET-PSMA
LACOG 0217 – IRONMAN
LACOG 0218 – Hercules
LACOG 0519 – PEACE III
LACOG 0620 – ExBAT
LACOG 1120 – RENAL REGISTRY
LACOG 1818 – Prostate Cancer Registry
LACOG 2018 – Foundation Penile

Gynecological
LACOG 0223 / GOG-3073 – ROSELLA
LACOG 0521 – MADONNA
LACOG 0820 – EVITA LATAM
LACOG 0920 – Senticol III
LACOG 1018 – PALBO in Ovarian Cancer
LACOG 1220 – CONOR

Head and Neck
LACOG 0319
LACOG 0720 – SMART-KEY

Lung
LACOG 0116 – LATINO LUNG
LACOG 0118 – RELANCE
LACOG 0120 – EAP durva lung cancer
LACOG 0322 – EDUR-BRA
LACOG 0821
LACOG 1918
LACOG 2218 – PACIFIC BRAZIL

Radiation
LACOG 0122 – RADIANT

Closed studies

Breast
LACOG 0111 – MGH
LACOG 0312 – METASTATIC BC
LACOG 0414
LACOG 0801 – GLICO

Genitourinary
LACOG 0415 – APA in Prostate Cancer
LACOG 0515 – Testicular Registry
LACOG 1518 – Bladder Cancer Registry

Gynecological
LACOG 0215 – EVITA

Head and Neck
LACOG 0318 – Induction

Lung
LACOG 0211 – ALK
LACOG 0417 – CNS MTX
LACOG 0618
Parsimony

Neuro
LACOG 0619

Other studies
LACOG 0213 – AUGMENT
LACOG 0214 – FINEP